TRxADE Health (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, has announced it will report its financial results for Q4 and year end 2021 later this month. The company said it will release the information on March 28, 2022, after market close via a press release. In addition, TRxADE executives will host a conference call and webinar the same day, scheduled to begin at 5 p.m. ET to discuss the report; that call will include a Q&A session. Interested parties can dial 1-877-425-9470 in the U.S. or 1-201-389-0878 internationally, and then use conference ID 13727651. Callers should dial in at least 10 minutes prior to the call. A playback of the call will be available through April 28, 2022. Callers can dial 1-844-512-2921 in the United States or 1-412-317-6671 internationally then enter replay pin number 13727651. A webcast will also be available for 30 days on the IR section of the TRxADE Group website or by clicking the webcast link above.
To view the full webinar, visit https://ibn.fm/LYiLk
To view the full press release, visit https://ibn.fm/qVUoW
About TRxADE Health Inc
TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The company operates the TRxADE drug procurement marketplace serving more than 12,700 members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient centric telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
